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The Wiskott-Aidrich syndrome is an X-linked recessive disorder characterized 
by reduced T  lymphocyte function including decreased antibody production to 
carbohydrate antigens, eczema, and thrombocytopenia with platelets of reduced 
size  and  function  (2,  3).  Allogeneic  histocompatibility-matched  bone-marrow 
transplantation  can  completely  correct  the  Wiskott-Aldrich  syndrome  by  the 
engraftment of normal  hematopoietic and lymphoid stem cells; partial engraft- 
ment in  two cases demonstrated  that the immune defects are due to a  primary 
T  lymphocyte defect (4).  Splenectomy has  transformed  both  platelet  size  and 
number  to  normal  in  Wiskott-Aldrich  syndrome  patients,  demonstrating  that 
these abnormalities are secondary manifestations of the disease (5). 
In an earlier study, we described structural  defects in surface components of 
both lymphocytes and platelets in the Wiskott-Aldrich syndrome (6). In lympho- 
cytes, a  previously undetected surface glycoprotein of apparent mol wt  115,000 
called  gpLll5,1  which  was  present  in  all  normal  donors  examined,  was  not 
detectable  in  three  Wiskott-Aldrich  patients;  whereas  in  platelets  of the  one 
Wiskott-Aldrich  syndrome patient  examined,  reduced amounts  and  restricted 
heterogeneity  were  detected of the  well-characterized  glycoprotein  Ib  (GPIb, 
reference 7), the Factor VIII-related von Willebrand receptor involved in platelet 
adhesion (8). 
The deficiency of the  lymphocyte surface glycoprotein gpL1 15 represents a 
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possible link between an X-chromosome defect and a broad functional immune 
deficiency. Questions arose about the nature and function of gpL 115. 
In  the  current  study we present  substantial  characterization  of the  gpL115 
molecule from peripheral  lymphocytes of normal  individuals and  from a  lym- 
phoblastoid cell line. Cumulatively, the characterization indicates that gpL 115 is 
not identical  to platelet  GPIb,  but shares  with  GPIb and  with  glycophorin  of 
erythrocytes, the property of being a  sialoglycoprotein with high content of O- 
linked (mucin-type acidic-type) carbohydrate moieties, gpL115 also shares char- 
acteristics with leukocyte sialoglycoprotein (LSGP), the rat and mouse thymocyte 
surface component responsible for peanut lectin agglutinability which consists of 
60% O-linked carbohydrate residues (9,  10). 
Materials and Methods 
Materials.  The sources of materials are as follows: galactose oxidase, soybean trypsin 
inhibitor,  and  /3-galactosidase from  Escherichia  coil (Worthington  Biochemical  Corp., 
Freehold, NJ); sialidase from Vibrio cholerae, 20 IU per mg protein, and lactoperoxidase 
(Calbiochem  Behring  Corp.,  American  Hoechst Corp.,  San  Diego,  CA); myosin  from 
chick muscle (Bethesda Research Laboratories, Inc., Gaithersburg, MD); sodium dodecyl 
sulfate (SDS) and Nonidet P40 (NP-40) (BDH Chemicals, Ltd., Poole, England); ultrapure 
urea  and  Coomassie  Brilliant  Blue (Schwarz/Mann  Div.,  Becton,  Dickinson  and  Co., 
Orangeburg,  NJ); sodium  [~5]iodide  and  sodium [SH]borohydride  (Amersham  Corp., 
Arlington Heights, IL); L-[sSS]methionine (New England Nuclear, Boston, MA); leupeptin 
(acetyI-L-leucyl-L-leucyl-argininal), 8-azaguanine,  polyethylene glycol (approximate mol wt 
of  1,000),  dithiothreitoi,  N-acetyi-~glucosamine,  D-galactose, a-methyI-D-mannoside, 
phosphorylase  a,  albumin,  carbonic  anhydrase,  2-mercaptoethanoi,  diisopropylfluoro- 
phosphate (DFP), sodium periodate (Sigma Chemical Co., St. Louis, MO); x-ray film (X- 
Omat, Eastman  Kodak Co., Rochester, NY); and intensifying  screens (Cronex Lightning 
Plus; E.I. Dupont de Nemours Co., Wilmington,  DE); acrylamide (Bio-Rad Laboratories, 
Richmond,  CA);  2,5-diphenyloxazole  (Fisher  Scientific  Co.,  Fair  Lawn,  NJ); creatine 
kinase (Boehringer Mannheim  Biochemicals, Indianapolis,  IN); pristane (2,6,10,14-tetra- 
methylpentadecane), iodoacetamide, and cyanogen bromide (Aldrich Chemical Co., Inc., 
Milwaukee, WI); formaldehyde-fixed, heat-killed Staphylococcus aureus (The Enzyme Cen- 
ter, Boston, MA); Ficoll-Paque and Sepharose-6B (Pharmacia,  Inc., Piscataway, NJ); rabbit 
antisera  to mouse whole IgG (Miles Laboratories, Inc.,  Elkhart,  IN); rabbit antisera  to 
mouse IgG 1, IgG2a, IgG2b, and IgG3 (Litton Bionetics, Charleston,  SC) and acid-citrate- 
dextrose, NIH formula A (Fenwal Laboratories, Div. of Travenol Labs., Inc.,  Deerfield, 
IL). 
Ca++/Mg  ++ free Hanks'  balanced salt solution  (HBSS), Dulbecco's Modified Eagle's 
Medium (DME), penicillin, streptomycin, L-methionine, and fetal bovine serum were from 
M. A. Bioproducts, Walkersville,  MD; fetal bovine sera were from Sterile Systems, Inc., 
Logan, UT; Gibco Laboratories, Grand Island, NY; and M.A. Bioproducts.  All sera were 
heat-inactivated  (56°C for  1 h).  Fetal  bovine serum for biosynthesis  experiments was 
dialyzed for 24 h at 4 °C against several changes of HBSS and sterilized by filtration  (0.22- 
#m Millipore filter).  Eagle's  Modified Minimum  Essential Medium (Earle's salts) lacking 
methionine was from Flow Laboratories, McLean, VA. 
Lentil lectin (Lens culinaris  lectin) was purified to homogeneity from lentil beans (Peak 
brand, D and D Bean Co., Greeley, CO) (11) and was coupled at 2.5 mg/ml resin in 0.1 
M NaHCO~,  pH 8.4,  0.1  M a-methyl-D-mannoside  to Sepharose-6B  activated by CNBr 
(12).  Wheat  germ  lectin  (Triticum  vulgaris  lectin)  (Bethesda  Research  Labs,  Inc.)  was 
coupled at 1.0 mg/ml in 0.1 M NaHCOa, pH 8.4, 0.1 M N-acetyl-~glucosamine to CNBr- 
activated Sepharose-6B  and peanut lectin (Arachis hypogaea lectin) (Sigma Chemical Co.) 
was coupled at 1.0 mg/ml in 0.1 M NaHCOa, pH 8.4, 0.1 M galactose. 
Lymphocytes.  Peripheral blood was collected from normal individuals  and from male 
children clinically diagnosed as having the Wiskott-Aldrich  syndrome (persistent  throm- REMOLD-O'DONNELL ET  AL.  1707 
bocytopenia with 20,000-50,000  platelets/#l, reduced platelet size, eczema, and variable 
immunodeficiency). Acid-citrate-dextrose was used as anticoagulant and the platelet-rich 
plasma was removed after centrifugation at 150 g for 8 rain. Unless otherwise specified, 
all procedures were done at room temperature. The pelleted cells were diluted  1:1  with 
Ca++/Mg  ÷+ free Hanks' balanced salt solution (HBSS) containing 20 #g/ml of the protease 
inhibitor leupeptin and were separated by FicolI-Hypaque centrifugation. The interface 
mononuclear cells were diluted with HBSS containing 2% fetal calf serum (FCS), pelleted 
at 300 g x  10 min, and incubated at 5 x  106/ml in RPMI  1640 with 2% FCS for 1 h at 
37 °C in plastic tissue culture flasks. The nonadherent cells were pelleted and, if necessary, 
washed by suspending and pelleting in HBSS with 2% FCS (1-3 cycles) to reduce platelet 
contamination to negligible levels as judged by visual examination (opalescence) and/or 
microscopic examinations.  The  lymphocytes were  washed  twice  in  cold  HBSS  before 
radioiodination or in cold PBS before SH-iabeling of surface carbohydrates. In the earliest 
experiments, heparin was used as anticoagulant and the platelet-depleted cell pellet was 
suspended in HBSS for Ficolt-Hypaque centrifugation. Adherent cells were removed by 
1 h culture in 10% human serum and the nonadherent cells were then washed three times 
by pelleting in HBSS. 
Cell Lines.  The human  T-lymphoblastoid cell lines  HSB (13) and CCRF-CEM  (14) 
were donated by Dr.  H.  Lazarus (Univ. of Miami Medical School) and grown in DME 
with 4.5 mg/ml glucose, 100 U/ml penicillin, 100/~g/ml streptomycin, and 10% fetal calf 
serum and washed before use by pelleting three times in HBSS or PBS. The nonsecreting 
mouse myeloma cell line NS-1  used for cell fusions was donated by Dr. D. McMahon Pratt 
(Brigham and Women's Hospital) and was grown in the above medium. 
Radioiodination of  Surface Protein Moieties.  Using a modified method (15), lymphocytes, 
7  125  CEM, or HSB cells were suspended at 2 X 10/ml in HBSS with 10 #M Na  I (200 #Ci/ 
ml for lymphocytes, 100 #Ci/ml for HSB or CEM cells) and 10 #g/ml lactoperoxidase at 
room temperature. H~O~ was added in five portions (each 12 #l/ml of 0.015%) over 10 
min. The reaction was terminated by adding 5-10 volumes of cold HBSS containing 0.1 
mM NaI, and the cells were washed by pelleting. 
Radiolabeling of Surface Carbohydrate Moieties.  In a modified method (16) to introduce 
3H-label into surface sialic acid residues, lymphocytes and CEM cells at 2-5 x  107 in 1 ml 
were incubated in  1 mM sodium periodate in  PBS at 4°C in the dark for 30  min and 
washed twice by pelleting in cold PBS. [3H]NaBH4 (50 #Ci in 5 #i cold 0.01  M  NaOH) 
was added  to the cells suspended in  1 ml PBS.  After 20 min at room temperature the 
radiolabeled cells were washed by pelleting in  cold HBSS.  To introduce  "H-label into 
desialylated surface moieties (17), lymphocytes and CEM cells at 2-5 X 107 in  1 ml were 
incubated with 0.1  IU/ml sialidase (Vibrio cholerae) and 25 #g/ml galactose oxidase (70- 
90 U/mg) for 30 min at room temperature and treated as described above. 
Biosynthesis of [*SS]Methionine-labeled Protein.  Lymphocytes or CEM cells were prein- 
cubated for 15 min in methionine-free medium, pelleted, and cultured at 1-4 x  107/ml 
in Eagle's Minimum Essential Medium lacking nonradioactive methionine with 100 U/ml 
of penicillin,  100 #g/ml of streptomycin, 5% dialyzed fetal bovine serum, and 80-160 
#Ci/ml [35S]methionine (900-1,100 Ci/mmol) for 1-2 h (CEM cells) or 18 h (lymphocytes). 
To  quantify  [sSS]methionine  incorporation  into  total  cell  protein,  duplicate  10-t*l 
samples were pipetted onto 2-cm squares of No. 3MM filter paper (Whatman) that were 
processed with trichloroacetic acid as described (18) and evaluated by scintillation count- 
ing. 
Preparation  of Monoclonal Antibodies.  Two  BALB/cByJ  female  mice  (The Jackson 
Laboratory, Bar Harbor, ME) received intravenous injections of 2  x  106 CEM cells in 
HBSS followed after 3 wk by 0.5 X 106 CEM cells and after further 5 wk by 2 x  106 CEM 
cells.  3 d  later, the mice were sacrificed and their spleen cells (1.4 and 2.2  x  l0 s cells) 
mixed at a 10:1 ratio with NS-1 myeloma cells and 35% polyethylene glycol and hybridized 
as described (19).  After  15 d, culture supernatants from the 53 largest colonies chosen 
from the  960  microtiter wells were assayed by immunoprecipitation (described below) 
with NP-40 extracts of 12SI-labeled CEM cells as antigen, followed by SDS-electrophoresis 
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antibody that immunoprecipitates 125I-gpL115CEM, was cloned twice at limiting dilution 
to yield the  cell  line  L10.  Antibody  isotypes were  determined  by double  diffusion  in 
Ouchterlony plates with isotype-specific antisera.  L10, an IgG1, has also been grown as 
ascites in pristane-treated BALB/cByJ mice. Other cell lines from the same fusions are 
L2, which  secretes an anti-gpL115  antibody, and  L1,  L8,  L4, and  L9,  which secrete 
antibodies recognizing other CEM surface proteins. As negative controls in immunopre- 
cipitation, we used L4 antibody, an IgG1 that immunoprecipitates an unidentified CEM- 
surface protein of-160,000 daltons and M3, a mouse monoclonai IgG1 generated against 
guinea pig macrophage surface antigens, (E.  Remold-O'Donnell et al., to be published) 
which does not immunoprecipitate l~SI-labeled human lymphocyte or CEM antigens. 
Lectin Affinity Chromatography.  Lymphocytes or CEM were extracted with 0.5%  NP- 
40,  10 mM Tris-HCI, pH 7.4,  150 mM NaC1,  I  mM diisopropylfluorophosphate, 3 mM 
iodoacetamide (1  ml extract per  1-8 ×  107 lympbocytes or  1-2 ×  107 CEM cells) for 3 
min at room temperature and 8 rain at 4°C.  Insoluble material was removed at  12,000 
gm~x ×  15 rain. The "NP-40 extracts" (0.8-2 ml) were applied to  1-ml columns of lentil 
lectin-Sepharose, wheat germ lectin-Sepharose or peanut lectin-Sepharose, which were 
washed with 0.3%  NP-40,  10 mM Tris-HCI pH 7.4,  150 mM NaCI (0.3% N.T.S.).  For 
each column, two fractions were collected, the "nonadherent" fraction and the "adherent 
fraction," the latter being the fraction eluted with 0.1  M a-methylmannoside in the case 
of lentil  lectin, 0.4  M N-acetylglucosamine in the case of wheat germ lectin, and 0.4  M 
galactose in the case of peanut lectin in 0.3% N.T.S. 
Sialidase Treatment.  l~I-labeled lymphocytes or CEM cells at 1-2 ×  107/ml in HBSS 
or NP-40 extracts of ~eSI-labeled cells were incubated for 30 min at room temperature 
with 2 mM diisopropylfluorophosphate without or with 0.02  IU/ml Vibrio  cholerae  siali- 
dase. 
lmmunoprecipitation.  Washed formaldehyde-fixed S. aureus were incubated for 30 min 
at  room temperature  with  rabbit  antiserum  to  mouse  IgG (20  #l  antiserum/6  mg of 
bacteria) and  the  resulting  bacteria-antibody complexes  washed  as  described  (20)  by 
pelleting once in Buffer B (10 mM Tris-HCl, pH 8.6, 0.1% SDS, 0.05% NP-40, 300 mM 
NaCl) and once in Buffer A  (12  mM sodium phosphate, pH 7.4,  200  mM NaCI). The 
complexes were incubated with hybridoma culture supernatant (200 #1/6 mg bacteria) for 
11/2  h  at  room  temperature  and  the  washing  procedure  was  repeated.  The  ternary 
complexes were  incubated  for  1-3  h  with  50-200  #1  x2~I-labeled or  [35S]methionine- 
labeled cell fractions. The resulting bacteria-second antibody-antibody-antigen complexes 
were washed twice and extracted for 2 min at 100°C with 2% SDS in 60 mM Tris-glycine 
buffer, pH 6.8, with or without 2% 2-mercaptoethanol. Fixed bacteria were removed by 
centrifugation. 
In a simpler variation used to screen hybridoma colonies, 75 #1 of hybridoma culture 
supernatant were incubated with 75 #1 of NP-40 extract of l~5I-labeled  CEM for 2 h at 
room temperature and then combined with 6 mg fixed S. aureus containing bound rabbit 
antibodies to mouse IgG. Incubation, washing, and extraction were as above. 
Two-dimensional Electrophoresis.  Two-dimensional isoelectrofocusing-SDS-electropho- 
resis  analysis  was  performed  according  to  a  modified  procedure  (2I,  22).  The  first 
dimension isoelectrofocusing tube gel was composed of 3.3% polyacrylamide, 9.2 M urea, 
and  3.2%  Triton X-100  with 0.4%  ampholytes (Ampholine,  LKB) of range pH 2.5-4, 
2%  of range pH  3.5-5,  2%  of range pH  5-7,  and  0.6%  of pH  3.5-10.  The sample 
dissolved in 9.5 M urea, 0.2%  NP-40, and 60 mM dithiothreitol was applied to the basic 
end and focused for  16  h  at 400  V  and  2  h  at  1,000  V. The pH values are averages 
measured after elution of 5 mm slices of duplicate gels with water. 
Polyacrylamide  Gel Electrophoresis  and Autoradiography.  NP-40  extracts and purified 
cell fractions were solubilized by heating with an equal volume of 2% SDS in 60 mM Tris- 
glycine buffer, pH 6.8, with or without 2% 2-mercaptoethanol for 2 min at 100°C. SDS 
electrophoresis (23) and autoradiography conditions were as described (24) with gels of 
7% polyacrylamide or of 7.5-14% exponential polyacrylamide gradients. The standard 
proteins  myosin,  /3-galactosidase,  phosphorylase  a,  albumin,  creatine  kinase,  carbonic 
anhydrase, and soybean trypsin inhibitor indicated mol wt of 200,000,  130,000, 94,000, REMOLD-O'DONNELL  ET  AL.  1709 
68,000, 40,000, 29,000, and 22,000, respectively. Polyacrylamide gels containing 35S- or 
3H-labeled proteins were prepared for fluorography by impregnating  with  10 w/v% 2,5- 
diphenyioxazole in dimethyl sulfoxide as described (25). 
Results 
Lentil  Lectin  Chromatography  of gpLll5 from  Lymphocytes and  Lymphoblastoid 
Cell Lines.  To characterize  its carbohydrate  moieties,  gpL115  was analyzed by 
affinity  chromatography  on  columns  of  lentil  lectin-Sepharose.  Lentil  lectin 
shows specificity for  mannose  (26),  a  core  component  of asparagine-linked  (N- 
linked)  carbohydrate  units,  l~SI-labeled-gpL115  of normal  lymphocytes  passed 
unretarded  through  lentil  lectin-Sepharose  columns (Fig.  1, left), indicating  that 
gpL115  contains  little  or  no  exposed  mannose  residues  and  suggesting  the 
absence of N-linked carbohydrate. 
Two long-term  lymphoblastoid cell lines HSB (14) and CEM (13) were surface 
radioiodinated.  Both  contain  ~SI-labeled  components  that  co-migrate  on  SDS- 
electrophoresis with gpL 115 of normal peripheral  lymphocytes (not shown). The 
component of apparent  mol wt 115,000 in CEM cells is the most prominent  l~sI- 
labeled cell surface protein.  On chromatography  of extracts of 125I-labeled CEM 
cells, the major  radiolabeled  115,000  mol wt component  was found to be lentil 
lectin-nonadherent  (Fig.  1, right) suggesting  its identity with gpL 115 of normal 
lymphocytes. 
Wheat  Germ Lectin  Chromatography  of gpLll5.  When  chromatographed  on 
wheat  germ  iectin-Sepharose,  12~I-labeled  gpL115  of normal  lymphocytes  was 
found totally in the adherent  fraction  (Fig.  2A,  le~). Wheat  germ lectin has two 
FIGURE  1.  Chromatography on lentil lectin-Sepharose of ~25I-labeled  surface polypeptides of 
normal lymphocytes (three left lanes) and the lymphoblastoid cell line CEM (three right lanes). 
In each case the Start fraction,  the  NP-40 extract  of 125I-labeled cells, is followed by the 
nonadherent  fraction  (Non Ad.) and  then  the adherent  fraction  (Ad., a-methylmannoside 
eluate). Shown is an autoradiograph  of an SDS-electrophoresis gel (nonreducing conditions) 
with tool wt × 10  -3 of marker proteins indicated on the left. 1710  HUMAN  LYMPHOCYTE  SURFACE  SIALOGLYCOPROTEIN 
FIGURE 2.  (A)  Chromatography  on  wheat  germ  lectin-Sepharose  of  ~25I-labeled  surface 
polypeptides of normal lymphocytes without (Native) and with (AsiMo) sialidase treatment of 
the starting fraction, an NP-40 extract. Shown is an autoradiograph of an SDS-electrophoresis 
gel (nonreducing conditions). The left three lanes show chromatography of a native extract, 
with the starting fraction (Start), the nonadherent fraction (Non Ad.), and the adherent fraction 
(Ad; N-acetylglucosamine eluate) indicated. The three lanes on the right show chromatography 
of a sialidase-treated extract. Positions of mol wt marker proteins and gpL 115 are indicated 
on the left. The shift in electrophoretic mobility of gpL115 after sialidase treatment can be 
noted by comparing Native  and Asialo starting  fractions.  Asialo-gpL115, designated by the 
arrows on the right, migrates with apparent mol wt 150,000; its identity as a species of gpL 115 
was verified by immunoprecipitation (shown below)? Note that native gpL115 from lympho- 
cytes is wheat germ lectin-adherent and asialo-gpL 115 is nonadherent.  (B) Chromatography 
on wheat germ lectin-Sepharose of l~5I-labeled surface polypeptides of CEM cells.  Details and 
findings are as in A, REMOLD-O'DONNELL  ET  AL.  1711 
specificities, binding both to N-acetylglucosamine (27, 28) and to clustered sialic 
acid  residues  (29,  30).  To  determine which of these specificities mediate  the 
binding  of  gpLll5,  the  starting  fraction,  an  NP-40  extract  of  1~I-labeled 
lymphocytes, was treated with sialidase to remove sialic acid. Sialidase treatment 
was found, first of all, to reduce the electrophoretic mobility of gpL115 from 
apparent mol wt  115,000 to apparent mol wt  150,000 (Fig. 2A, comparison of 
"Native" and "Asialo" starting fractions). This large reduction in electrophoretic 
mobility suggests that gpL 115 has significant sialic acid content. On chromatog- 
raphy, asialo-gpL115 was found in the wheat germ lectin-nonadherent fraction 
(Fig. 2A, right), indicating that native gpL115 adheres to wheat germ lectin via 
sialic acid residues and does not adhere via N-acetylglucosamine residues. 
The native  115,000  mol wt  125I-labeled  molecule from CEM cells, like lym- 
phocyte gpL115,  was found to be wheat germ lectin-adherent  (Fig.  2B,  le~). 
Sialidase  treatment  shifted  this  molecule  to  apparent  mol  wt  150,000  and 
converted it to a wheat germ lectin-nonadherent form (Fig. 2 B, right), strongly 
suggesting that this CEM surface molecule is identical to gpL 115 of lymphocytes. 
Radiolabeling  of the Carbohydrate Moieties of gpL115.  Surface  carbohydrate 
moieties were labeled by treating lymphocytes with periodate followed by [3H]- 
NaBH4,  which converts terminal  9-carbon  sialic acid residues to 3H-labeled  7- 
carbon 5-acetamido-3,5-dideoxy-L-arabino-2-heptulosonic acid residues (31). 3H- 
label was found in several lymphocyte surface glycoproteins, including a  com- 
ponent of apparent mol wt 115,000, presumably gpL115 (Fig. 3, le~).  Lympho- 
cytes were also treated with sialidase-galactose oxidase followed by [SH]NaBH4, 
which yields 3H-labeled asiaio-glycoproteins. The 3H-labeled asialo-glycoproteins 
of lymphocytes migrate with apparent tool wt _150,000  (Fig.  3). After similar 
treatments of CEM cells, the major 3H-labeled native surface glycoprotein has 
apparent  mol  wt  115,000  and  the  major  ~H-labeled  asialo-glycoprotein  has 
apparent mol wt 150,000 (Fig. 3). 
Isoelectrofocusing ofgpLll5.  On two-dimensional analysis (isoelectrofocusing- 
SDS  electrophoresis)  of partially  purified  fractions,  l~SI-labeled gpLll5  from 
CEM cells was found as a broad band or "streak," primarily in the extreme acidic 
region  at  pH  4.1  (Fig.  4,  top). On  the  other  hand,  sialidase-treated  gpL115 
focuses as  a  defined  spot  at  pH  ~5.0  (Fig.  4,  bottom). Identical  behavior  on 
isoelectrofocusing was found for native and sialidase-treated 125I-labeled gpL 115 
from lymphocytes (not shown). The large difference in the behavior of native 
and sialidase-treated  gpL115  on isoelectrofocusing indicates a  prominent role 
for multiple sialic acid residues in determining the physiochemical characteristics 
of gpL115 (see Discussion). 
Peanut Lectin Chromatography ofgpL115.  Peanut lectin shows specificity for 
the disaccharide Gal/31-3GalNAc (32), a sequence found in mucin-type O-linked 
saccharides  (33).  When  extracts  of  l~SI-labeled  lymphocytes  were  chromato- 
graphed on peanut lectin-Sepharose,  gpL115  was found to be peanut lectin- 
nonadherent (Fig.  5A, left). Sialidase-treated  gpL115  from lymphocytes, how- 
ever, was found to be peanut lectin-adherent (Fig. 5A, right). 125I-labeled native 
gpL 115 from CEM cells was also found to be peanut lectin-nonadherent, and 
the sialidase-treated form to be peanut lectin-adherent (Fig. 5 B), which provides 
further evidence that the gpL115 molecules from CEM cells and lymphocytes 1712  HUMAN LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN 
FIGURE 3.  SH-labeled  surface glycopeptides  of  normal peripheral lymphocytes  (two left lanes) 
and CEM cells (two right  lanes). Intact cells were reacted with [~H]NaBH4 after periodate 
treatment to generate reactive carbonyl groups in terminal sialic  acid residues (Native)  or after 
treatment with sialidase and galactose oxidase (Asialo).  Shown is a fluorograph of NP-40 cell 
extracts  fractionated  by  SDS-electrophoresis under  nonreducing  conditions with mol  wt 
(×10 -s) indicated on the right. Arrow on the left indicates the position of native lymphocyte 
gpL 115 and the major co-migrating SH-labeled native glycopeptide of CEM. Arrow on the 
right indicates the position of the major CEM SH-labeled  asialo-glycopeptide  which migrates 
with apparent mol wt 150,000. 
are identical.  The peanut lectin chromatography findings indicate that gpL1 15 
contains the sequence sialic acid-Gall31-3GalNAc, a sequence that is characteristic 
for O-linked, mucin-type saccharide residues. 
Generation  of Anti-gpLl l5 Monoclonal  Antibody.  Hybridoma  technique  was 
used to generate a  cell line secreting monoclonal antibody to gpL 115. The cell 
line, L 10, was generated using CEM cells as the immunizing agent. L 10 antibody 
is an  IgG1  molecule that  immunoprecipitates  lzSI-labeled native and  sialidase- 
treated  gpL1 15  (Fig.  6).  Both  gpL1 15  from  lymphocytes and  CEM  cells are 
immunoprecipitated by L 10 antibody (Fig. 6), further demonstrating their iden- 
tity. 
Synthesis of gpL115 by Lymphocytes.  Since detection of gpL 1 15  relied exclu- 
sively on surface labeling techniques, we sought to determine whether gpL 1 15 
is a  biosynthesis product of lymphocytes and CEM cells or an acquired surface 
component. Lymphocytes from five normal donors cultured with [35S]methionine 
at  2-4  ×  107/ml  were found to incorporate 21%  +  3%  of added  radioactivity 
into  trichloroacetic acid-precipitable  protein  in  18  h.  CEM  cells,  in  contrast, REMOLD-O'DONNELL ET  AL.  1713 
FIGURE  4.  Two-dimensional analysis of native and sialidase-treated1251-1abeled  gpL l15 from 
CEM cells. Shown is an autoradiograph of two-dimensional gels with isoelectrofocusing on the 
horizontal axis (pH gradient is indicated) and SDS-electrophoresis under reducing conditions 
on the vertical axis (tool wt marker positions indicated on the right). NP-40 extracts of 1~sI- 
labeled CEM  cells were  incubated  without  (Native) or with (Asialo) sialidase. The former 
fraction was then purified  by wheat germ iectin chromatography  and the latter  by peanut 
lectin chromatography.  Note that sialidase treatment shifts gpL 115 to an isoelectric  point that 
1 ',n3 T  is less acidic and  more sharply defined.  Identical  results were  obtained  when  I-labeled 
gpL1 15 was first purified  (by lentil lectin and wheat germ lectin chromatography)  and then 
incubated without (Native)  or with (Asialo)  sialidase (not shown). 
incorporated >60%  within  2  h.  On immunoprecipitation,  L10 antibody precip- 
itates  a  [SSS]methionine-labeled  component  of apparent  mol  wt  115,000  from 
lymphocytes and  CEM  cells  that  was  not  found  in  immunoprecipitates  of two 
control  monoclonal  IgG1 antibodies  (Fig.  7).  The  [SSS]methionine-labeled  com- 
ponent precipitated by L10 antibody co-migrates with 125I-gpL115 under reduc- 
ing and nonreducing conditions  (not shown), thus establishing that lymphocytes 
and CEM cells synthesize gpL 115. 
Defect  in  gpLIl5  in  Lymphocytes  of  Wiskott-Aldrich  Syndrome  Patients 
Lymphocytes of patients  with  the  Wiskott-Aldrich  syndrome and  normal indi- 
viduals  were  radioiodinated  and  their  surface  components  examined  by  SDS 
electrophoresis and  autoradiography.  In all,  lymphocytes from 8  patients  were 1714  HUMAN  LYMPHOCYTE  SURFACE  SIALOGLYCOPROTEIN 
FIGURE 5.  (A and B) Chromatography on  peanut  lectin-Sepharose of l~5I-labeled surface 
polypeptides of normal lymphocytes (A) and CEM cells (B) without (Native, three left lanes) 
or with (Asialo,  three right lanes) sialidase treatment. Details as in Fig. 2, A and B. Note that 
native gpL 115 of lymphocytes and CEM cells (arrow on the left) is peanut lectin-nonadherent 
and that asialo-gpL115 (arrows on the right) is the major 1~SI-labeled peanut lectin-adherent 
protein. 
examined  in  12  experiments,  lzSI-labeled  gpL1 15  was  found  to  be deficient  in 
lymphocytes  of all  patients.  However,  the  levels  of  125I-gpLl15  varied,  being 
nondetectable  in  patient  1  (Fig.  1  of reference  6)  patients  2,  3,  and  5  (Fig.  8) 
and detectable,  but decreased relative to levels in normal lymphocytes, in patients 
4,  6,  7, 8  (Fig.  8). REMOLD-O'DONNELL  ET  AL.  1715 
FIGURE 6.  Immunoprecipitation of native and sialidase-treated t25I-labeled  gpL 115 by L 10 
monoclonal antibody.  NP40 extracts of normal  lymphocytes and CEM cells were incubated 
without (Native) or with (Asialo) sialidase and  immunoprecipitated  with hybridoma  culture 
supernatant  of Ll0  cells (lanes  1,  3,  5,  7)  or  M3  cells  (lanes  2,  4,  6,  8).  Shown  is  an 
autoradiograph  of an  SDS electrophoresis gel (reducing conditions) with tool wt X  10  -~ of 
marker proteins indicated on the left. 
FIGURE 7.  Immunoprecipitation  of gpL115  labeled  biosynthetically with  [sSS]methionine. 
Normal lymphocytes and CEM ceils were cultured with [sSS]methionine. gpLl 15-containing 
fractions were prepurified by NP-40 extraction and wheat germ lectin chromatography and 
immunoprecipitated with L10,  (lanes I  and 4) or L4 (lanes 2 and 5) or M3 (lanes 3 and 6). 
Shown is a fluorograph of an SDS electrophoresis gel (reducing conditions) with the position 
indicated of m~sI-labeled gpL 115 which was electrophoresed in parallel. F
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FIGURE  9.  ~251-1abeledsurfaceproteinsofnormallymphocytesandCEMcellsaftertreatment 
with varying concentrations of sialidase. Normal lymphocytes  and CEM cells were treated with 
A, E,  no  additive;  B, F, 0.002; C, G, 0.007; and D, H, 0.02 IU/ml sialidase (Vibrio cholerae), 
washed, radioiodinated, and extracted  with NP-40. Shown is an autoradiograph  of an SDS 
electropboresis gel (nonreducing conditions) with the position of marker proteins and native 
gpL115 indicated by the large arrows on the left. Note that sialidase treatment  generates 
partially desialylated species of gpL115  (small arrows) that  migrate  as discrete  bands of 
decreasing mobility. Higher sialidase concentrations did not further alter the electrophoretic 
mobility of gpL115 (not shown). A pattern identical to the right lane was found when CEM 
cells were treated with sialidase from Clostridium perfringens, (0.32 U/ml; Bethesda Research 
Laboratories; not shown). 
In addition, an ~25I-labeled polypeptide of apparent mol wt 135,000 (indicated 
in Fig. 8 by dots on the left) was found in lymphocytes of two patients (patient 3 
and patient  6) and  on  one of two analyses of the cells of patient  2.  This  125I- 
labeled  135,000 mol wt component was not detected in lymphocytes of normal 
individuals and did not co-migrate with asialo-gpL 115 (apparent mol wt 150,000; 
not shown). 
Thus,  lymphocytes of patients  with  the  Wiskott-Aldrich  syndrome are  char- 
acterized by the absence or the deficiency of gpL 115 molecules that are accessible 
to  surface  radioiodination.  In  addition,  lymphocytes of some  Wiskott-Aldrich 
syndrome patients  contain  a  surface  polypeptide of apparent  mol  wt  135,000 
not found in lymphocytes of normal individuals. 
Treatment of normal lymphocytes or CEM cells with limiting concentrations 
of  sialidase was found to generate species ofgpL 115 of  decreasing electrophoretic 
mobility (Fig.  9).  The partially desialylated species of gpL115 display varying, 
but discrete, apparent electrophoretic mobilities intermediate between those of 
the native and the "asialo"-gpL115 molecules (Fig. 9).  2 This finding introduces 
2 The sialidase-treated  gpL 115 species  of apparent mol wt 150,000 has been referred to as "asialo" 
since higher sialidase concentrations do not further alter its mobility. We cannot, at this stage, rule 
out the presence of residual resistant sialyl moieties. 1718  HUMAN  LYMPHOCYTE  SURFACE  SIALOGLYCOPROTEIN 
the possibility that the abnormal  135,000  mol wt component found in lympho- 
cytes of some Wiskott-Aidrich syndrome patients is a partially desialylated var- 
iant(s) of gpL 115. 
Discussion 
gpL115,  the  lymphocyte surface glycoprotein that  is  deficient in  Wiskott- 
Aldrich  syndrome, is  a  sialoglycoprotein that  can  be  radiolabeled  in  protein 
moieties by  lzSI-lactoperoxidase and  in  carbohydrate moieties by  [SH]NaBH4. 
gpL 115 can be labeled by culturing lymphocytes with [SSS]methionine, indicating 
that it is synthesized by lymphocytes. 
Comparison of radioiodinated surface proteins of lymphocytes and the lym- 
phoblastoid cell line CEM by electrophoresis, isoelectrofocusing, sialidase treat- 
ment, lectin affinity chromatography, and immunoprecipitation established that 
gpL115  is  also  present  on  the  surface of the  CEM  cells,  a  finding  used  to 
advantage in the generation of a monoclonal antibody to gpL115. The designa- 
tion of CEM  cells as a  suitable source establishes the opportunity for isolation 
and chemical analysis of gpL 115. Through the use of surface marker antigens, 
CEM  has  been  shown  to  be  a  cell  line  of early thymocyte origin  (34),  thus 
implying that thymocytes, which were not examined in this study, also express 
surface gpLl 15. 3 
gpL115  was  identified through  its  deficiency in  Wiskott-Aldrich  syndrome 
patients (6) and has also been found defective in lymphocytes of two non-Wiskott 
immunodeficient patients. 4 ~25I-labeled gpL115 was not immunoprecipitated by 
monocional antibodies directed against the surface antigen CALLA (references 
35,  36; common acute lymphoblastic leukemia antigen; antibodies supplied by 
Dr. J.  Ritz, Dana Farber Cancer Institute), thus establishing the nonidentity of 
gpL 115 and CALLA. Likewise, gpL 115 was not immunoprecipitated by mono- 
clonal anti-T12  antibody (reference 37;  supplied  by Dr.  S.  Schlossman,  Dana 
Farber Cancer Institute), demonstrating the nonidentity of the surface antigens 
T12 and gpL115. 
The quantity of sialic acid on gpL115 is not known, but appears to be large 
since desialylation dramatically alters the physical behavior of the molecule. On 
SDS electrophoresis, desialylation shifts gpL115 from a mobility corresponding 
to  tool  wt  115,000  to  a  mobility  corresponding  to  mol  wt  150,000.  Good 
correlation of mol wt with electrophoretic mobility in the presence of SDS has 
been  established  for  a  wide  range  of polypeptides  (38)  and  the  behavior  of 
gpL 115 is, thus, atypical. Anomalous behavior on SDS electrophoresis is a feature 
of glycoproteins with high content of carbohydrate and is caused by the inability 
of carbohydrate to bind SDS (39, 40). 5 
On  isoelectrofocusing, sialidase treatment shifts gpL115  from a  very broad 
band  or  "streak,"  primarily in  the extreme acidic region (pH  4.1)  to a  well- 
defined "spot" at pH 5. We do not know why the native molecule is found as a 
broad streak. Heterogeneity at the level of sialylation is a possibility, but would 
not explain the finding that the streak of native gpL115 extends to pH regions 
Using  fluorescent  techniques,  LI0  anti-gpL115  monoclonal  antibody  stains  99%  of normal 
lymphocytes and thymocytes (R. Parkman et al., to be published). 
4 R. Parkman et al., manuscript in preparation. 
5 We have at present no estimate of the true molecular weight of gpL 115. REMOLD-O'DONNELL  ET  AL.  1719 
less acidic than  the spot of sialidase-treated  gpL115  (observed  in  five of five 
experiments).  We  favor  the  explanation  that  native  gpL115  is  incompletely 
focused, i.e., that the rate of focusing of native gpL 115 is atypically slow due to 
its elongated conformation enforced by its high sialic acid content. 
Lymphocytes of patients with the Wiskott-Aldrich syndrome are characterized 
by a  defect in gpL115.  12SI-labeled  gpL115 was deficient in eight patients; the 
extent of the deficiency varied from nondetectable levels (four patients) to levels 
that are decreased relative to normal individuals (four patients). In addition, an 
l~I-labeled surface protein of apparent mol wt 135,000, which was not found in 
normal individuals, was detected in three of eight Wiskott-Aldrich patients. We 
speculate  that  this abnormal  component is a  variant  of gpL115. 6 gpLll5  of 
normal individuals can be converted to apparent  mol wt  135,000  by treating 
intact lymphocytes with limiting sialidase concentrations (Fig. 9). 
The thesis that a single defective gene in Wiskott-Aldrich syndrome codes for 
both  the  defective  lymphocyte and  platelet  surface  components gpL115  and 
GPIb is unlikely since the molecules are not identical, i.e., they do not co-migrate 
on electrophoresis (not shown). We also did not detect partial  identity, in that 
GPIb (l~SI-labeled and [3H]NaBH4-1abeled) was not immunoprecipitated by L 10 
anti-gpL115 monoclonal antibody and 125I-gpL115 was not immunoprecipitated 
by a polyclonal antibody to GPIb/glycocalicin (not shown; rabbit antisera supplied 
by Dr. G. A. Jamieson, The American National Red Cross, Bethesda, MD). 
A  more likely hypothesis is that the concomitant defect of gpL 115 and GPIb 
in Wiskott-Aldrich syndrome results from a single defective processing element, 
possibly  a  synthesis  enzyme  such  as  a  glycosyi  transferase,  or  a  degradation 
enzyme. The current study indicates that gpL115, like GPIb, is one of a  small 
group of glycoproteins with high content of O-linked carbohydrate  units (see 
below); and it is, thus, likely that they share some biosynthesis and/or degradation 
steps. 
Glycoprotein carbohydrate moieties are of two types. The N-linked "complex" 
and  "high  mannose"  units  consist  typically of 8-14  monosaccharide  residues 
(sialic acid, galactose,  fucose, mannose, and N-acetylglucosamine) linked to as- 
paragine via N-glycosidic bonds, gpL 115 is lentil lectin-nonadherent, suggesting 
the absence of N-linked carbohydrate.  The second type, the "O-linked"  units, 
also called "mucin-type" or "acidic type" because of the high sialic acid content, 
are linked to serine or threonine via O-glycosidic bonds. These units are generally 
small, consisting of three, four, or six residues. For example, in glycophorin O- 
linked units consist of galactose, N-acetylgalactosamine, and two terminal sialic 
acid residues (41) and in platelet GPIb,  they also contain N-acetylglucosamine 
(42). Typically, mannose is not found. 
A  few glycoproteins consist of >50%  O-linked  carbohydrate;  these include 
erythrocyte  glycophorin  (43),  platelet  GPIb  (7),  "masking"  glycoproteins  on 
certain tumor cells (44, 45), and LSGP (leukocyte sialoglycoprotein; 9), a rat T 
lymphocyte and thymocyte surface component. LSGP may be the counterpart 
in the rat of gpL115.  LSGP displays the same unusual behavior as gpL115 on 
lentil lectin (46) and peanut lectin chromatography (10);  its asialo-form  is the 
6 When  lymphocytes from a  suitable patient become available, this hypothesis will be tested by 
immunoprecipitation with L 10 antibody. 1720  HUMAN  LYMPHOCYTE  SURFACE  SIALOGLYCOPROTEIN 
major  peanut  iectin-adherent  surface  glycoprotein  of rat  thymocytes and  T 
lymphocytes (10). 
gpL115 adheres to wheat germ lectin, but asialo-gpL115 does not, indicating 
that wheat germ lectin-adherence is due to clustered sialic acid residues on the 
native  molecule.  Clustered  sialic  acid  is  a  feature  of glycoproteins with  high 
content of O-linked sugar, gpL115 does not adhere to peanut lectin, but asialo- 
gpL 115 does--a very important finding since peanut lectin shows specificity for 
the disaccharide galactose/3(1-3)-N-acetylgalactosamine.  These findings indicate 
that native gpL 115 contains the sequence sialic acid-galactose/3(1-3)-N-acetylga- 
lactosamine, a sequence particular to O-linked, mucin-type carbohydrate units. 
This study establishes similarity of the carbohydrate portions of the lymphocyte 
and  platelet  components altered  in  Wiskott-Aldrich  syndrome.  Like gpL115, 
GPIb and its soluble form glycocalicin (8) adhere to wheat germ lectin (7) and 
asialo-GPIb adheres to peanut lectin (8).  GPIb (glycocalicin) consists to 60%  of 
carbohydrate that appears to be exclusively mucin-type units linked to serine and 
threonine (7, 42). 
Due  to  sialic  acid  content,  glycoproteins with  high  O-linked  carbohydrate 
content are  thought to adopt extended  conformation and  to confer  negative 
charge  characteristics  required  in  cell-cell  interactions  (9).  In  certain  mouse 
adenocarcinomas a surface sialoglycoprotein with >50% O-linked carbohydrate, 
referred  to as a  "masking" glycoprotein, is thought to confer on the cells the 
capacity to invade allogeneic and xenogeneic hosts (44, 45).  Similarly, sialidase 
treatment of mouse lymphoma cells exposes cryptic tumor antigens on glycolipid 
molecules that  are,  themselves, devoid of sialic acid  (47).  Finally,  removal of 
sialic  acid  from  lymphocytes  has  been  shown  to  induce  their  loss  from  the 
circulation (48). 
The  cumulative  findings  suggest that  the  defect(s)  in  the  sialoglycoprotein 
gpL 115  in  the Wiskott-Aldrich syndrome adversely affect(s) the ability of the 
lymphocytes to interact with other cells and/or to survive in circulation. 
Summary 
gpL1 15 is a  lymphocyte surface component that is deficient in patients with 
the  X-chromosome-linked  immune  deficiency  Wiskott-Aldrich  syndrome  (6). 
The glycoprotein nature of gpL 1 15 is demonstrated through labeling in carbo- 
hydrate moieties by [SH]NaBH4 and its synthesis by lymphocytes through labeling 
with [35S]methionine. Native gpL1 15 adheres to wheat germ lectin-Sepharose 
and  sialidase-treated  gpL1 15  does  not adhere,  indicating that  native  gpL1 15 
adheres via clusters of sialic acid residues. When tested on peanut lectin, which 
shows specificity for the disaccharide Galt31-3GalNAc,  gpL1 15 is nonadherent 
and sialidase-treated gpL 1 15 is adherent, indicating the presence of the sequence 
sialic  acid-Gal~l-3GalNAc,  which  is  characteristic  for  O-linked  (mucin-type, 
acidic-type) carbohydrates.  A surface glycoprotein with all the above character- 
istics was found on the lymphoblastoid cell line CEM.  CEM  cells were used as 
immunogen to generate  the monoclonal antibody  L10,  an  IgG~,  which binds 
native and sialidase-treated gpL 1 15. Sialidase-treatment of ~L 115 signifiCantly 
alters its physical properties, reducing its electropboretic mobility and changing 
its  behavior  on  isoelectrofocusing.  Cumulatively,  these  findings  indicate  that 
gpL 1 15, like glycophorin of erythrocytes and GPIb of platelets, is a  sialoglyco- REMOLD-O'DONNELL  ET  AL.  1721 
protein with significant quantities of O-linked carbohydrate. 
On treatment  with limiting sialidase concentrations, gpL 115  of normal lym- 
phocytes is transformed into a series of partially desialylated species of decreasing 
electrophoretic mobility. This finding resembles the situation with lymphocytes 
of  some  Wiskott-Aldrich  syndrome  patients.  Lymphocytes  of eight  Wiskott- 
Aldrich  syndrome patients  were found to be deficient in  l~I-labeled  gpL115. 
Lymphocytes from three of these patients displayed an abnormal ~25I-component 
of apparent mol wt 135,000. 
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Note added in proof'. After submission of the manuscript, we became aware of a report 
describing  F10-44-2,  an  LSGP-like glycoprotein of tool wt  105,000  on  human  blood 
mononuclear cells (Dalchau, R., J. Kirkley, and J. w. Fabre.  1980. Monoclonal antibody 
to a human brain-granulocyte-T lymphocyte antigen probably homologous to the W  3/ 
13 antigen of the rat. Eur. J. Immunol. 10:745). This molecule may be identical to gpL 115. 
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